Abstract 937
Background
The prognosis of type 4 or large type 3-gastric cancer is extremely poor. Despite various perioperative adjuvant therapies; as JCOG0501, peritoneal recurrence is still difficult to control. Since the clinical efficacy of chemo-radiotherapy was suggested for the treatment of advanced gastric cancer, chemo-radiotherapy is a promising strategy for curatively resectable type 4 or large type 3-gastric cancer. This multicenter, phase II study evaluated the efficacy and safety of radiotherapy combined with S-1 plus cisplatin for this target.
Methods
Eligibility criteria included pathologically confirmed gastric adenocarcinoma with macroscopically type 4 or large type 3, without peritoneal or distant metastases. Patients received preoperative chemo-radiotherapy with S-1 80 mg/m2/day from Day 1 to 14 and cisplatin 60 mg/m2 on Day 1, and radiotherapy at a total dose of 40 Gy in 20 fractions was delivered for 4 weeks, followed by D2 gastrectomy, and received S-1 monotherapy for one year postoperatively. The primary endpoint was the pathological complete response rate (% protocol completion). Secondary endpoints were safety, overall survival, and the response rate (RR). The sample size was calculated to be 30 cases, under the hypothesis of expected % pathological complete response rate of 15% and threshold pathological complete response rate of 2% with one-sided testing at the 10% significance level and power of 90%.
Results
From November 2012 to April 2018, 20 patients were enrolled. A median age of 20 patients was 67 years. Nineteen patients had protocol operation, and two of them showed pathological complete response (10.5%; 95% confidence interval 1.3–33.1%, p < 0.001). During preoperative chemotherapy, grade 3/4 neutropenia occurred in 25%, and grade 3/4 non-hematological adverse events occurred in 10%. The incidence of adverse events related to surgery was occurred in 31.6% patients. There were no treatment-related deaths. Follow-up for long-term survival is continuing. Notably the pathological RR (residual tumor < 2/3) was 100% (19/19).
Conclusions
Preoperative chemo-radiotherapy with S-1 plus CDDP is a safe and promising treatment for type 4 or large type 3 gastric cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Osaka Gastointestinal Cancer Chemotherapy Study Group.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2107 - Role of Individualized Intervention(s) on Quality of Life (QOL) and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women with Early-Stage Breast Cancer (BC): MyChoice Study
Presenter: Shahid Ahmed
Session: Poster Display session 2
Resources:
Abstract
5812 - Correlation between the density of tumor-infiltrating lymphocytes, immune cell subsets in tumor stroma and response to systemic therapy in breast cancer
Presenter: Cvetka Grasic Kuhar
Session: Poster Display session 2
Resources:
Abstract
4734 - BRCA1/2 Testing in HER2- Advanced Breast Cancer (ABC): Results from the European Component of a Multi-Country Real World Study
Presenter: Michael Patrick Lux
Session: Poster Display session 2
Resources:
Abstract
1686 - In vitro and in vivo rescue of resistance to BET inhibitors by targeting PLK1 in triple negative breast cancer.
Presenter: Cristina Nieto-jiménez
Session: Poster Display session 2
Resources:
Abstract
5020 - Neoadjuvant endocrine therapy in combination with melatonin and metformin in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
5082 - Melatonin and metformin in neoadjuvant chemotherapy in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
2642 - Patient-tailored tamoxifen dosing based on an increased quantitative understanding of its complex pharmacokinetics: A novel integrative modelling approach
Presenter: Anna Mueller-Schoell
Session: Poster Display session 2
Resources:
Abstract
2461 - Lack of benefit of neoadjuvant pertuzumab in high risk HER2 positive breast cancer. A retrospective case-control study of 355 cases with biomarker analysis.
Presenter: Manuela Tiako Meyo
Session: Poster Display session 2
Resources:
Abstract
4776 - Targeting CDCA3 to improve chemotherapy response in triple-negative breast cancer patients
Presenter: Kenneth O'Byrne
Session: Poster Display session 2
Resources:
Abstract
1674 - Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Presenter: María Del Mar Noblejas López
Session: Poster Display session 2
Resources:
Abstract